Results 131 to 140 of about 238,371 (341)
Emergency Medicine International, 2013 Background. The NT-ProBNP/BNP test has been validated as a marker for determining the etiology of acute dyspnea. In the setting of end-stage renal disease on hemodialysis (ESRD on HD), the utility of the NT-ProBNP/BNP test has not been validated.
Shaffer R. S. Mok +3 more
doaj +1 more source
Midregional pro-Adrenomedullin in addition to b-type natriuretic peptides in the risk stratification of patients with acute dyspnea: an observational study [PDF]
, 2009 The identification of patients at highest risk for adverse outcome who are presenting with acute dyspnea to the emergency department remains a challenge.
Mihael Potocki +13 more
core +1 more source
Journal of the American Medical Association (JAMA), 2021 B. Pieske +8 more
semanticscholar +1 more source
Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe
ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani +11 more
wiley +1 more source
Lean ZSF1 rats in basic research on heart failure with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 1474-1478, April 2025.Abstract Aims ZSF1 obese rats harbouring two mutant leptin receptor alleles (Leprcp and Leprfa) develop metabolic syndrome and heart failure with preserved ejection fraction (HFpEF), making them a widely used animal model in cardiometabolic research.
Petra Büttner +10 more
wiley +1 more source
Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure. [PDF]
, 2014 OBJECTIVES: The GUIDE-IT (Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure) study is designed to determine the safety, efficacy, and cost-effectiveness of a strategy of adjusting therapy with the goal of achieving and
Adams, Kirkwood F. +15 more
core +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy +15 more
wiley +1 more source
Folia Medica Indonesiana, 2017 Heart failure (HF) is the final common stage of many diseases of the heart. NT-proBNP levels are increased in HF and correlate well with ventricular wall stress and severity of HF. Combination therapy with Bisoprolol and ACE-inhibitor decreases NT-proBNP
Reine Risa Risthanti +2 more
doaj +1 more source
Sensitivity and specificity of NT-proBNP to detect heart failure at post mortem examination [PDF]
, 2018 NT-proBNP, a marker of cardiac failure, has been shown to be stable in post mortem samples. The aim of this study was to assess the accuracy of NT-proBNP to detect heart failure in the forensic setting.
Augsburger, Marc +5 more
core
Italian National Conference on Sensors, 2019 Surface-plasmon-resonance (SPR) is a quantum-electromagnetic phenomenon arising from the interaction of light with free electrons at a metal-dielectric interface.
Dorin Harpaz +5 more
semanticscholar +1 more source